A
Acorn Biolabs
Acorn Biolabs - Accessible and Affordable Stem Cell Collection
About Acorn Biolabs
Acorn Biolabs specializes in the collection and storage of stem cells, making regenerative medicine accessible and affordable. The company operates in the healthcare market, focusing on individuals who wish to preserve their younger, healthier cells for future medical use. Acorn Biolabs employs a non-invasive method to collect cells, typically from hair follicles, which are then stored for potential future applications in personalized healthcare and advanced analytics. The business model revolves around a subscription-based service where clients pay for the initial collection and ongoing storage of their cells. Revenue is generated through these subscription fees, as well as potential future services related to the use of stored cells in medical treatments. Acorn Biolabs aims to provide peace of mind by ensuring that clients have a viable healthcare resource available as they age, addressing the growing demand for personalized and regenerative medicine solutions.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- Toronto, Canada
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A5 investors entered at this stage
Merz Aesthetics
Telus- MIMDE Investments
Leslie Group- LHLee Li Holdings
Series B and later1 investor entered at this stage
FedDev Ontario
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Acorn Biolabs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Acorn Biolabs on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
